Avapritinib(CAS: 1703793-34-3)

Avapritinib is a selective inhibitor of the PDGFRA D842V mutation, used in the treatment of gastrointestinal stromal tumor (GIST) with the PDGFRA D842V mutation and systemic mastocytosis (SM) with one or more mutations in the KIT gene.

Avapritinib is primarily used for treating patients with unresectable or metastatic GIST harboring the PDGFRA D842V mutation and systemic mastocytosis with one or more KIT mutations. It is also being studied for other potential uses in oncology.

Avapritinib is generally considered safe when used as directed. However, it can cause side effects such as diarrhea, nausea, and fatigue. Patients should be monitored for these effects and other potential side effects. Always follow the prescribed dosage and medical advice.

Avapritinib should be stored at room temperature (15-30°C) and protected from light. It should be kept in a tightly closed container and away from moisture and heat to maintain its efficacy and stability.